Sarepta Therapeutics Announces Update on Regulatory Review of SRP-9001
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Wall Street ends sharply higher as Waller remarks ease rate hike fears
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Raymond James Stays Sidelined on Sarepta (SRPT) Citing 'heavily eclipsed market opportunity' and 'binary risk heading into EMBARK'
May 24, 2023 10:52 AM EDTRaymond James analyst Danielle Brill reiterated a Market Perform rating and {REMOVEPT} price target on Sarepta Therapeutics (NASDAQ: SRPT).
The analyst comments "
oday, Sarepta announced that the FDA has pushed back the PDUFA date for SRP-9001 to June 22 (was May 29). The reason for the delay was reportedly to provide more time to complete the regulatory review, labeling discussions,... More
William Blair Defends Sarepta Therapeutics (SRPT)
May 24, 2023 9:50 AM EDTWilliam Blair analyst Tim Lugo reiterated an Outperform rating and {REMOVEPT} price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "We believe that SRP-9001 represents both a meaningful therapy for patients and a significant opportunity for Sarepta. Competing programs have faced safety concerns that have led to the halting of trials,... More
Citi on Sarepta Therapeutics (SRPT): 'We expect shares to trade towards the $120s today', 'Buy on weakness'
May 24, 2023 9:06 AM EDTCiti analyst Neena Bitritto-Garg reiterated a Buy rating and $204.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "This mornings announcement of a PDUFA delay (decision expected by June 22) is a surprise to us given FDAs commitment to sticking to... More
RBC Capital Defending Sarepta Therapeutics (SRPT), 'we believe weakness presents a buying opportunity'
May 24, 2023 8:48 AM EDTRBC Capital analyst Brian Abrahams reiterated an Outperform rating and $218.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)
The analyst comments "This morning, SRPT announced that the PDUFA date for '9001 will be delayed until June 22, 2023, from May 29th, to give the FDA additional time to complete the review, which we note had been a topic of intense investor debate in recent weeks. Additionally, SRPT also announced that the initial label will be targeted towards 4-5 year olds. While the push-out on timelines may on the surface seem to be a negative, our sense... More
Sarepta Therapeutics (SRPT) Falls 9% After Saying FDA Needs Additional Time to Complete Review of SRP-9001
May 24, 2023 8:10 AM EDT(Updated - May 24, 2023 8:10 AM EDT)
Sarepta Therapeutics (NASDAQ: SRPT) Falls 9% After Saying FDA Needs Additional... More
